Article information
Full text is only aviable in PDF
Bibliografía
[1.]
R. Sabés.
Análisis coste-efectividad de acarbosa en el tratamiento de pacientes con intolerancia a la glucosa.
Gac Sanit, 18 (2004), pp. 431-439
[2.]
J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso, STOP-NIDDM Trial Research Group.
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
JAMA, 290 (2003), pp. 486-494
[3.]
J.L. Chiasson, R.G. Josse, R. Gomis, H. Hanefeld, M. Karasik, M. Laakso.
Acarbose for prevention of type 2 diabetes mellitus: the Stop-NIDDM randomised trial.
Lancet, 359 (2002), pp. 2072-2077
[4.]
T. Kaiser, P.T. Sawicki.
Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data.
Diabetologia, 47 (2004), pp. 575-580
[5.]
J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso, STOP-NIDDM Trial Research Group.
Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
Diabetologia, 47 (2004), pp. 969-975
Copyright © 2005. Sociedad Española de Salud Pública y Administración Sanitaria
